BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety leadin (SLI), of first-line (1L) encorafenib (E) plus cetuximab (C) 6 chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要